您所在位置： &
&nbsp&&nbsp&nbsp&&nbsp
燃烧的夜晚Pharma_industry_2015_PipelineReport_（，_PharmaExec）.doc 17页
本文档一共被下载：
次 ,您可全文免费在线阅读后下载本文档。
下载提示
1.本站不保证该用户上传的文档完整性，不预览、不比对内容而直接下载产生的反悔问题本站不予受理。
2.该文档所得收入(下载+内容+预览三)归上传者、原创者。
3.登录后可充值，立即自动返金币，充值渠道很便利
燃烧的夜晚Pharma_industry_2015_PipelineReport_（，_PharmaExec）.doc
你可能关注的文档：
··········
··········
2015 Pipeline Report: Burning Bright
Nov 1, 2014?By:?Josh Baxt?PHARMACEUTICAL EXECUTIVE
Tracking new therapies as they wind their way through development, regulatory approval, and payer acceptance can be like waiting for paint to dry and then repainting in a different color. It's a slow process and far from linear.
This is especially true for potentially groundbreaking drugs, disruptive technologies that completely upend markets and patient care. The lag time between that first flickering glimmer of hope and an accepted therapy can be measured in decades. And, all too often, agents that seem hopeful in the lab and early clinical trials fizzle on further investigation.
But then there are those rare moments when the stars align and truly astounding therapies make their way into the world, providing improved care and big returns. In the next few years, cancer immunotherapies seem likely to enter the pantheon of big winners. And they may not be alone. Besides the buzz around a cure for hepatitis C virus, there are exciting drugs for heart failure and cholesterolemia coming into play. On a smaller scale, companies are embracing new therapies for rare diseases. Stem cells are making real forays into late-stage trials.
This year's pipeline report will check in on these emerging technologies, as well as potential therapies to address metabolic and neurodegenerative diseases. There's a lot to like in the pipeline and more than a little competitive drama to make it really interesting.
Immuno-Oncology: The Elegant Splution
A Crowded Field
The combo conundrum
Targeted oncology new medicines
A revolution in heart failure
Raising HDL, Lowering LDL
Diabetes and obesity
Neurodegenerative diseases
Rare diseases
Stem cells
Odds and ends
Payer politics
Immuno-oncology: The elegant solution
For Trekkers, there's nothing better than watching a Klingon or Romulan ship lose its invisibility cloak and get blasted out of space. On the cellular level, similar action is driving
正在加载中，请稍后...}